Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
PRESS RELEASE H1 2026 results: well-managed growth and improved profitability H1 2026 revenue of €124.5m (+7.3%): growth driven by the Erevo acquisition and the integration of Novaprove and the DIS business, up 1.4% like-for-likeAnnual recurring revenue (ARR) of €111.1m at June 30, 2026, +8.8%, with a strong organic componentCurrent EBITDA of €33.3m (+11.9%), with the EBITDA margin increasing to 26.8% from 25.7% in H1 2025Current operating income of €23.7m (+11.9%): the current operating margin
Equasens Activates the Business Continuity Plan for its subsidiary ASCA in Chessy (France,77) Villers-lès-Nancy, September 22, 2026, 5:45 p.m. CEST – Equasens (ISIN: FR0012882389 – Ticker: EQS), a leader in digital healthcare solutions, announces that the headquarters and warehouse of its subsidiary ASCA, a specialist in the deployment of electronic labeling solutions for pharmacies, were affected by a fire, the source of which has now been extinguished. ASCA, a subsidiary of the Equasens Group,
Strong growth in maintenance and subscriptions revenue (+8.4% to €55.7 million), including solid organic growth (+4.7%) in H1 2026 Positive momentum in the French Pharmacy business, driven in particular by software innovations and services (+4.3% in H1 2026), and in Italy, supported by growth in the customer base and new hardware solutions (+42.4% in H1 2026) Successful launch of the new digital training offering (virtual classrooms) introduced by the MEDICAL SOLUTIONS Division Villers-lès-Nancy
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.